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Original Article

Hospital-Initiated Care Bundle, Posthospitalization
Care, and Outcomes in Adults with Asthma
Exacerbation
Makiko Nanishi, MDa, Valerie G. Press, MD, MPHb, Joseph B. Miller, MD, MSc, Carly Eastin, MDd, Taruna Aurora, MDe,
Erin Crocker, PA-C, MPHa, Michimasa Fujiogi, MDa, Carlos A. Camargo, Jr., MD, PhD, FAAAAIa, and
Kohei Hasegawa, MD, MPHa Boston, Mass; Chicago, Ill; Detroit, Mich; Little Rock, Ark; and Richmond, Va

What is already known about this topic? Hospitalization for asthma exacerbation is an opportune setting for initiating
preventive care for high-risk patients. However, little is known about the effect of implementing an evidence-based preventive care bundle during hospitalization on subsequent risk of asthma exacerbation.
What does this article add to our knowledge? In this study of adults hospitalized for asthma exacerbation, implementation of a hospital-initiated care bundle not only improved the quality of post-hospitalization asthma care but also
reduced the rate of severe asthma exacerbation up to 30%.
How does this study impact current management guidelines? The present study underscores the importance of
implementing evidence-based preventive asthma care in patients hospitalized with asthma exacerbation.
BACKGROUND: Hospitalization for asthma exacerbation is an
opportune setting for initiating preventive efforts. However,
hospital-initiated preventive asthma care remains underdeveloped and its effectiveness is uncertain.
OBJECTIVE: To examine the effectiveness of a hospital-initiated
asthma care bundle on posthospitalization asthma care and
clinical outcomes.
METHODS: Prospective multicenter study of adults (18-54
years) hospitalized for asthma exacerbation in 2017 to 2019.
During the hospitalization, we implemented an asthma-care
bundle (inpatient laboratory testing, asthma education, and
discharge care), and prospectively measured chronic asthma care
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(eg, immunoglobulin E testing, specialist care) and asthma
exacerbation (ie, systemic corticosteroid use, emergency department [ED] visit, hospitalizations) outcomes. By applying a
self-controlled case series method, we examined within-person
changes in these outcomes before (2-year period) and after
(1-year period) the bundle implementation.
RESULTS: Of 103 adults hospitalized for asthma exacerbation,
the median age was 40 years and 72% were female. Compared
with the preimplementation period, the postimplementation
period had improved posthospitalized asthma care, including
serum speciﬁc immunoglobulin E testing (rate ratio [RR] 2.18;
95% conﬁdence interval [95% CI] 0.99-4.84; P [ .051) and
evaluation by asthma specialist (RR 2.66; 95% CI 1.77-4.04;
P < .001). Likewise, after care bundle implementation, patients
had signiﬁcantly lower annual rates of systemic corticosteroid
use (4.2 vs 2.9 per person-year; RR 0.70; 95% CI 0.61-0.80;
P < .001), ED visits (3.2 vs 2.7 per person-year; RR 0.83; 95%
CI 0.72-0.95; P [ .008), and hospitalizations (2.1 vs 1.8 per
person-year; RR 0.82; 95% CI 0.69-0.97; P [ .02). Stratiﬁed
analyses by sex, race/ethnicity, and health insurance yielded
consistent results.
CONCLUSIONS: After hospital-initiated care bundle implementation, patients had improved posthospitalization care and
reduced rates of asthma exacerbation. Ó 2021 American Academy
of Allergy, Asthma & Immunology (J Allergy Clin Immunol Pract
2021;-:---)
Key words: Asthma exacerbation; Hospitalization; Quality of
care; Asthma management; Outcomes

INTRODUCTION
Asthma is a signiﬁcant health problem in the United States. In
2018, 25 million individuals had asthma,1 with an estimated
1
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Abbreviations used
COPD- Chronic obstructive pulmonary disease
ED- Emergency department
ICS- Inhaled corticosteroids
IgE- Immunoglobulin E
IL- Interleukin
MARC-41- The 41st Multicenter Airway Research Collaboration
RCT- Randomized controlled trial

direct health cost of $50 billion.2 Asthma exacerbations
contribute to a substantial portion of this problem—approximately 1.7 million emergency department (ED) visits and
180,000 hospitalizations in 2016 alone.3 In this context, the
U.S. government has identiﬁed improving asthma care as an
objective in Healthy People 2030, with a goal to reduce asthma
exacerbations, ED visits, and hospitalizations.4
Despite its clinical and public health importance, recent
studies have demonstrated a suboptimal quality of ED,5-9 inpatient,10-12 and transitional12,13 care in patients with asthma
exacerbation. For example, a retrospective study of hospitalized
patients with asthma reported that guideline-recommended
transition of care to specialists was suboptimal (only 27% of
hospitalized adults received a referral to an asthma specialist at
hospital discharge).10 Within the sparse literature, clinical trials
of adults with asthma exacerbation have examined the effect of
single or limited elements of asthma care—such as asthma education,14-16 individual action plan,17-19 or facilitated
referral20—on subsequent asthma outcomes. Although hospitalization for asthma exacerbation is an opportune setting for
initiating high-quality asthma care for these costly and high-risk
patients, little is known about the effect of implementing an
evidence-based preventive care bundle21 during hospitalization
on subsequent risk of asthma exacerbation.
To address the knowledge gap, we conducted a prospective
multicenter study of adults hospitalized for asthma exacerbation
to examine the effectiveness of a hospital-initiated asthma care
bundle on posthospitalization asthma care and clinical outcomes.

METHODS
Study design, setting, and participant
This is a multicenter, prospective, before-after study—the 41st
Multicenter Airway Research Collaboration (MARC-41)—that investigates the effectiveness of the hospital-initiated preventive care
bundle in adults hospitalized for asthma exacerbation. By applying a
self-controlled case series design, we compared each participant’s rate
of outcomes over a 3-year period (ie, 2 years before vs 1 year after the
implementation of the care bundle). This design enables each
participant to function as his or her own control.22 Accordingly, it
has a major advantage that effects of any time-invariant covariates
(eg, the genetics, sex, race/ethnicity, site) are implicitly controlled,
thereby mitigating unmeasured confounding.22-25
In 2017 to 2019, we enrolled adults (aged 18-54 years) with a
physician diagnosis of asthma, current use of inhaled corticosteroids
(ICS), and a history of frequent severe exacerbations (deﬁned by 2
bursts of systemic corticosteroids [3 days each] in a 1year period26)
who were hospitalized for asthma exacerbation at 1 of the 5
geographically diverse U.S. hospitals—Henry Ford Hospital
(Detroit, MI), Massachusetts General Hospital (Boston, MA),
University of Arkansas for Medical Science (Little Rock, AR),
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University of Chicago Medical Center (Chicago, IL), and Virginia
Commonwealth University Medical Center (Richmond, VA). We
limited the study to patients aged 18 to 54 years in order to minimize misspeciﬁcation with chronic obstructive pulmonary disease,
according to previous studies.6,10 We excluded patients with nonadherence to ICS (ie, use of ICS once a week or less—based on the
screening interview and medical record review at enrollment) and
those without a permanent address or phone number. The institutional review board at each of the participating hospitals approved
the study (as a quality improvement study). Informed consent was
obtained from all study participants.

Exposure—hospital-initiated asthma care bundle
Immediately after hospital admission, the participating site
implemented the inpatient asthma care bundle consisting of 3 major
areas with a total of 10 core elements (Table E1; available in this
article’s Online Repository at www.jaci-inpractice.org): (1) laboratory testing (serum total immunoglobulin E [IgE] as well as complete blood count with differential [including eosinophil
quantiﬁcation]); (2) education (development of written action plan,
education of inhaler use technique, issuing peak ﬂowmeter, and
smoking cessation assistance [for smokers]); (3) hospital discharge
(or transitional) care (prescription of systemic corticosteroids,
modiﬁcation of ICS, and instruction/scheduling of follow-up by
asthma specialist). In addition to these core (mandatory) elements,
the sites also implemented optional elements (eg, pharmacy, asthma
care manager consult) based on the availability of resources at each
site. These optional elements did not contribute to the overall
bundle examined. The item selection of the care bundle was based
on the national and international asthma guidelines,27,28 systematic
literature review of high-quality evidence (including the Cochrane
Database of Systematic Reviews and meta-analysis of clinical trials),
and input from the multidisciplinary project team (eg, allergists,
emergency physicians, internists, pulmonologists). The overall goal
of the bundle was to reduce the risk of severe asthma exacerbations
after the index hospitalization.

Outcome measures
The primary clinical outcome was severe asthma exacerbation—
the use of systemic corticosteroids for 3 or more days, ED visit, or
hospitalization for asthma exacerbation—during the pre- and postimplementation periods, according to previous studies.26,29,30 The
secondary (process measure) outcomes were asthma care, including
laboratory testing (total and speciﬁc IgE measurement, environmental allergen skin testing), adjustment to long-term controller
medications (eg, initiation of biologic agents), and evaluation by an
asthma specialist (eg, allergist, pulmonologist). We measured these
outcomes—in both the preimplementation period (retrospectively)
and the postimplementation period (prospectively)—through
structured interviews and medical record review by nonblinded investigators using a standardized protocol, which has been used in
previous studies.6,10,31 Structured interviews and medical record
review were conducted at enrollment and during hospitalization as
well as at 1 month, 6 months, and 12 months after enrollment to
abstract the data on asthma care (including the electronic documentation of medication use), clinical outcomes, medical history,
and laboratory testing during the pre- and postimplementation
periods. All data were reviewed at the EMNet Coordinating Center
at Massachusetts General Hospital, and site investigators were
queried about missing data and discrepancies identiﬁed by data
checks.

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on August 30, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

NANISHI ET AL

J ALLERGY CLIN IMMUNOL PRACT
VOLUME -, NUMBER -

TABLE I. Characteristics of adults hospitalized for asthma
exacerbation*
n [ 103

Characteristics

Patient characteristics
Demographics
Age, y, median (IQR)
Female sex, n (%)
Race/ethnicity, n (%)
Non-Hispanic White
Non-Hispanic Black
Hispanic ethnicity
Others
Health insurance, n (%)
Private
Public
No insurance
Household income, $, median (IQR)†
Having primary care physician, n (%)
Current smoking, n (%)z
BMI, kg/m2, median (IQR)x
Medical history
History of eczema, n (%)
History of allergic rhinitis, n (%)
Coexistent illnesses, n (%)k
COPD
Gastroesophageal reﬂux
Psychiatric disorder
Congestive heart failure
Pneumonia
Asthma-related history
ED visit for asthma in the
preimplementation period, n (%)
Hospitalized for asthma in the
preimplementation period, n (%)
Frequency of hospitalizations, median
(IQR)
History of intubation for asthma, n (%)
Current use of oral corticosteroids, n (%)
Current use of ICS, n (%)
Current use of long-acting beta-agonist, n (%)
Current use of leukotriene receptor
antagonists or modiﬁers, n (%)
Asthma Control Test in the past 4 wk,
median (IQR)
Having PEF meter
Having PEF measured in the past 4 wk{
Having asthma action plan
Laboratory values during hospitalization
WBC, cells/mL, mean (SD)
Eosinophils, cells/mL, mean (SD)
Serum total IgE level, IU/mL, mean (SD)#
Presentation and inpatient course
Initial hospitalization location, n (%)
ED observation unit
Hospital ward or stepdown unit
ICU
Mechanical ventilation**

40 (32-49)
74 (72)
19
69
12
3
38
62
3
37,942
95
22
35

(18)
(67)
(12)
(3)
(37)
(60)
(3)
(27,540-54,164)
(92)
(21)
(28-43)

32 (31)
66 (64)
13
12
10
7
6

(13)
(12)
(10)
(7)
(6)

96 (93)
79 (77)
2 (1-5)
30
45
103
70
54

(29)
(44)
(100)
(68)
(52)

9 (7-12)
76 (74)
42 (55)
47 (46)
10,480 (4,130)
297 (430)
412 (880)

55
36
12
12

(53)
(35)
(11)
(12)
(continued)

3

TABLE I. (Continued)
Characteristics

Disposition, n (%)
Discharged to home
Left against medical advice

n [ 103

101 (98)
2 (2)

BMI, Body mass index; ICU, intensive care unit; IQR, interquartile range; PEF, peak
expiratory ﬂow; WBC, white blood cell count.
*Percentages are not equal to 100 because of rounding.
†Estimated from patient’s residence ZIP code.
zAmong 97 patients who gave the information of smoking status.
xAmong 90 patients who gave the information of body height and weight.
kIncluding COPD, pneumothorax, pneumonia, nasal polyps, rhinitis, sinusitis, vocal
code dysfunction, signiﬁcant arrhythmia, congestive heart failure, psychiatric
disorder (eg, schizophrenia), and gastroesophageal reﬂux.
{Among 76 patients who had a PEF meter before the index hospitalization.
#Among 77 patients who underwent serum total IgE measurement during the index
hospitalization.
**Including noninvasive and invasive positive-pressure ventilation.

Statistical analysis
In the current study, we applied a self-controlled case series
method to multicenter data. This design relies on within-individual
comparisons in a study sample with both the exposure and the
outcomes of interest.22 Speciﬁcally, to examine the effectiveness of
the care bundle on the posthospitalization asthma care and clinical
outcomes, we examined the within-individual changes for each
outcome between the pre- and the postimplementation periods. We
ﬁt conditional Poisson regression models to estimate rate ratios
(RRs) with 95% conﬁdence intervals (95% CIs)—with the preimplementation period (2-year period) as the reference period—for
the postimplementation 1-year period. To account for the difference
in period intervals, the model incorporated an offset term (ie, natural
logarithm of the interval). Because each patient is matched to her or
his own reference period, the RRs from the conditional Poisson
regression model are equivalent to having ﬁxed effects in the model.
We conducted a series of sensitivity analyses. First, in the stratiﬁed analyses that examine the potential heterogeneity in the effect of
care bundle,32-35 we repeated the analysis with stratiﬁcation by sex,
race/ethnicity, insurance, baseline smoking status, obesity (body
mass index  30 kg/m2), history of intubation, recent oral corticosteroid use, and initial disposition (ie, ED observation unit,
hospital ward or stepdown, and intensive care unit). Second, to
minimize the potential misclassiﬁcation with chronic obstructive
pulmonary disease (COPD), we have conducted a subgroup analysis
excluding patients with a history of COPD. Third, to address the
potential effect of increased availability of biologic agents in recent
years, we repeated the analysis by excluding patients who initiated
anti-interleukin-4 (IL-4)/IL-5 therapy after hospital discharge.
Fourth, we repeated the analysis by dividing the postimplementation
period into 2 6-month intervals (1-6 months and 7-12 months after
the index hospitalization). Lastly, to address the point that exacerbations events are recurrent and nonindependent, we modeled the
outcome events as binary variables. The original target sample size
was 90 patients hospitalized for asthma exacerbation. We estimated
that the study would have had a power of greater than 80% to detect
a 30% decrease in the incidence of severe asthma exacerbation, from
2.40 per year in the preimplementation period to 1.68 per year in
the postimplementation period at a 2-sided signiﬁcance level of .05.
We analyzed the data using R version 4.0.1 (R Foundation for
Statistical Computing, Vienna, Austria). All P values were 2-tailed,
with P less than .05 considered statistically signiﬁcant.
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FIGURE 1. Within-individual comparisons of chronic asthma care between the pre- and the postimplementation periods. Arrows indicate
that the 95% CI of the RR exceeds the lower or higher limit of the x-axis. *Averaged over the 2-y period (a total of 206 person-years)
before the implementation of the hospital-initiated care bundle. †In the 1-y period (a total of 102.5 person-years) after the implementation of the hospital-initiated care bundle (including the index hospitalization). zRRs are for post- vs pre- (reference) implementation
periods within individuals, as estimated by conditional Poisson regression models accounting for the difference in period intervals. xSerum
specific IgE measurement after the index hospitalization. ǁIncluding dupilumab, benralizumab, mepolizumab, and reslizumab.

RESULTS
Patient characteristics
The MARC-41 study enrolled 103 adults hospitalized for
asthma exacerbation at 1 of the 5 participating hospitals during
2017 to 2019. Data of the 12-month postimplementation period
were available in 102 patients (99%), with the other patient
contributing to 6-month postimplementation period data owing
to loss to follow-up (ie, a total of 1,230 person-month followup). In this cohort, the median age was 40 years (interquartile
range, 32-49 years); 72% were women, 67% non-Hispanic
Black, and 12% Hispanic (Table I). In addition, 60% had
public health insurance and 3% had no insurance. As expected,
the study patients had a large asthma burden in the preimplementation period, reﬂected by 93% having at least 1 ED
visit and 77% having hospitalization for asthma exacerbation; the
index hospitalization was consistent with their chronic asthma
trajectory. Despite their substantial morbidity, patients reported
suboptimal quality of asthma care components in the preimplementation period, such as only 46% of patients having an
asthma action plan prior to their index hospitalization. At the
index hospitalization, 53% were admitted to the observation
unit, 35% to the ward or stepdown unit, and 11% to the
intensive care unit.
Comparisons of asthma care between the pre- and
the postimplementation of care bundle
After implementation of a hospital-initiated asthma care bundle
during the index hospitalization, the patients had improved quality
of chronic asthma care (Figure 1). For example, after the implementation of the care bundle, there was a nonsigniﬁcant increase
in the rate of speciﬁc IgE measurement (RR 2.18; 95% CI 0.994.84; P ¼ .051) and a signiﬁcant increase in the rate both for antiIL-4/IL-5 therapies (RR 10.1; 95% CI 1.62-192.4; P ¼ .04) and
for asthma specialist visit (RR 2.66; 95% CI 1.77-4.04; P < .001)
with adjusting for the difference in the period interval. In the
sensitivity analyses, despite their limited statistical power, the
association of care bundle implementation with an increased rate

of asthma specialist visits was similar across sex (Table E2; available
in this article’s Online Repository at www.jaci-inpractice.org),
race/ethnicity (Table E3; available in this article’s Online
Repository at www.jaci-inpractice.org), and health insurance
(Table E4; available in this article’s Online Repository at www.
jaci-inpractice.org) strata.

Comparisons of clinical outcomes between the
pre- and the postimplementation of care bundle
After the implementation of the in-hospital care bundle, the
study patients had a signiﬁcantly lower rate of severe asthma
exacerbation (Figure 2). Speciﬁcally, the annualized rate of systemic corticosteroid use decreased from 4.2 per person-year in
the preimplementation period to 2.9 per person-year in the
postimplementation period, with a corresponding RR 0.70 (95%
CI 0.61-0.80; P < .001). Likewise, there was a signiﬁcant
reduction in the rate for both ED visits (3.2 vs 2.7 per personyear; RR 0.83; 95% CI 0.72-0.95; P ¼ .008) and hospitalizations (2.1 vs 1.8 per person-year; RR 0.82; 95% CI 0.69-0.97;
P ¼ .02) after implementation of the asthma care bundle.
In the sensitivity analyses, despite the relatively limited sample
size, the relationship between care bundle implementation and
decreased rate of severe asthma exacerbation was generally
consistent across the sex (Table E5; available in this article’s
Online Repository at www.jaci-inpractice.org), race/ethnicity
(Table E6; available in this article’s Online Repository at www.
jaci-inpractice.org), and health insurance (Table E7; available
in this article’s Online Repository at www.jaci-inpractice.org)
strata. For example, the rate of ED visits and hospitalizations
signiﬁcantly decreased in both non-Hispanic White and Hispanic individuals, whereas the estimated effect was not signiﬁcant
in non-Hispanic Black individuals (Pinteraction < .01 and
Pinteraction ¼ .02, respectively; Table E6). With stratiﬁcation by
insurance, the estimated downward effects were also consistent
with the main analysis in both public and private insurance
strata. Likewise, similar relationships were observed in the
stratiﬁed analysis by smoking status (Table E8; available in this
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FIGURE 2. Within-individual comparisons of annualized incidence of severe asthma exacerbations between the pre- and the
postimplementation periods. *Averaged over the 2-y period (a total of 206 person-years) before the implementation of hospital-initiated
care bundle. †In the 1-y period (a total of 102.5 person-years) after the implementation of the hospital-initiated care bundle. zRRs are for
post- vs pre- (reference) implementation periods within individuals, as estimated by conditional Poisson regression models accounting for
the difference in period intervals.

article’s Online Repository at www.jaci-inpractice.org), obesity
(Table E9; available in this article’s Online Repository at www.
jaci-inpractice.org), intubation history (Table E10; available in
this article’s Online Repository at www.jaci-inpractice.org), oral
systemic corticosteroid use (Table E11; available in this article’s
Online Repository at www.jaci-inpractice.org), and disposition
(Table E12; available in this article’s Online Repository at www.
jaci-inpractice.org). In the subgroup analysis of patients without
COPD, the ﬁndings did not materially change (Table E13;
available in this article’s Online Repository at www.jaciinpractice.org). In the sensitivity analysis excluding patients
who initiated anti-IL-4/IL-5 therapy during the postimplementation period, the primary inference did not change
materially—the annualized rate of systemic corticosteroid use
decreased, with corresponding RR 0.71 (95% CI 0.62-0.81; P <
.001; Table E14; available in this article’s Online Repository at
www.jaci-inpractice.org). In the analysis dividing the postimplementation into 2 6-month periods, the rate reduction
remained signiﬁcant during the 7 to 12 months after the index
hospitalization. (Tables E15 and E16; available in this article’s
Online Repository at www.jaci-inpractice.org). Lastly, in the
analysis modeling the outcome events as binary variables, the
ﬁndings were also consistent—reduced rate of ED visits with a
corresponding RR of 0.21 (95% CI 0.07-0.70; P ¼ .01;
Table E17; available in this article’s Online Repository at www.
jaci-inpractice.org).

DISCUSSION
In this self-controlled case series analysis of a multicenter
prospective study of 103 adults hospitalized for asthma exacerbation, the implementation of a hospital-initiated care bundle
was associated with a signiﬁcant improvement in posthospitalization asthma care. Speciﬁcally, our data demonstrated
an increase in the rate of biologic agent use and asthma specialist
visit. Furthermore, there was a signiﬁcant improvement in the
clinical outcomes—an approximately 20% to 30% decrease in
the rate of subsequent severe asthma exacerbations, deﬁned by
the use of systemic corticosteroids, ED visits, or hospitalizations.
The current study demonstrated the effectiveness of an evidencebased, hospital-initiated care bundle on both chronic asthma care
and clinical outcomes in adults with severe asthma exacerbation.

In agreement with our ﬁndings, previous studies—mostly
focusing on individual elements of asthma care—have reported
reductions in asthma disease burden.14,36-38 For example, in a
single-center randomized controlled trial (RCT) of children and
adults with asthma exacerbation in the ED, Zeiger et al37 found
that, compared with continued management from nonspecialists,
facilitated asthma specialist care not only increased the use of ICS
but also decreased the frequency of asthma exacerbations and ED
revisits. Furthermore, in another single-center RCT of adults hospitalized for asthma exacerbation in 1996 to 1999, Castro et al38
reported that, compared with conventional care, multifaceted
asthma care intervention (based on the 1997 Expert panel Report 2
[EPR-2] guidelines) reduced readmissions for asthma as well as
health care (both direct and indirect) costs. In contrast, earlier reports have also shown no signiﬁcant change in clinical outcomes.17,39-41 For example, a Cochrane systematic review of 12
RCTs of educational intervention on adults with asthma exacerbation in the ED did not show a signiﬁcant reduction in ED revisits.39 These apparent discrepancies may be attributable to the
differences in study design, setting, target populations, interventions of interest, or any combination of these factors.
Regardless, the validity of our inference is strengthened by the selfcontrolled case series design. Its major advantage is that each individual serves as his or her own control and, hence, mitigates any
time-invariant confounding, which cannot be addressed in conventional observational studies.22 In addition, the study design
removes between-individual variations, thereby yielding more precise estimates despite the relatively small sample size. The current
study meets the assumptions of self-controlled case series in which
we modeled transient exposures (ie, implementation of care bundle)
and acute outcome events (ie, asthma exacerbations).22 The current
multicenter study builds on these prior reports and extends them by
demonstrating the effectiveness of an evidence-based care bundle on
both chronic asthma care and clinical outcomes in patients hospitalized with asthma exacerbation.
There are several potential explanations for the observed reductions in the frequency of severe asthma exacerbation after
implementation of the hospital-initiated care bundle. First, the
care bundle was, by deﬁnition, multifaceted (not as an isolated
item) and was implemented in the inpatient setting—a time of
heightened awareness and interest in health matters—reducing
the outcome rates, at least partially, through an improvement in
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both inpatient and posthospitalization care. Indeed, our data
showed that the implementation of the bundle signiﬁcantly
improved posthospitalization asthma care (eg, the modest increase in biologic agent use and improved follow-up rate by an
asthma specialist). Second, it is also possible that, after the
implementation of asthma education, the patients changed their
health behaviors (eg, better medication adherence), which the
current study did not directly measure after the hospital
discharge. Third, nonbundle elements of the study (eg, follow-up
interviews) might have had an incremental beneﬁt while its
contribution is unlikely to have been substantial. However,
despite the observed beneﬁt of the care bundle, the morbidity
burden of these patients remained large. This is partly because
the implementation and effectiveness of the care bundle were
imperfect in this real-world setting. Indeed, the implementation
rate of some bundle elements was relatively low—67% for instruction for a follow-up visit with an asthma specialist and 31%
for an appointment of a follow-up visit with an asthma specialist.
Only 52% had a specialist visit during the postimplementation
period whereas the rate signiﬁcantly increased after the care
bundle implementation. A prompt referral to a specialist at
hospital discharge continued to be a challenge for administrative,
ﬁnancial, system-wide, and transportation reasons.42 In addition,
the current study did not directly intervene on postdischarge
asthma care during the follow-up period (eg, guidelineconcordant use of chronic asthma medications by the primary
care physician). Furthermore, the observed heterogeneity of the
effect between the race/ethnicity groups also suggests the potential need for context-speciﬁc implementations43; it also could
have been due to the small subgroup sample sizes. Notwithstanding the complexity, the identiﬁcation of an effective
hospital-initiated preventive care bundle is an important ﬁnding.
Our data, along with the previous studies, present cautious
optimism that implementation of the evidence-based hospitalinitiated asthma care bundle can not only improve the quality of
asthma care but also reduce asthma morbidity burden.

Limitations
The study has several potential limitations. First, the data
measurement relied, in part, on medical record review for the
assessment of bundle implementation, asthma care, and outcomes;
consequences of under documentation are possible. However, a
prior study demonstrated that our data ascertainment methods
had a high interrater agreement, including k coefﬁcient of 0.95
(almost perfect) for clinical outcomes.6 Second, we retrospectively
measured the outcomes during the preimplementation period
whereas we prospectively measured the outcome during the
postimplementation period. This might have up- or downwardly
biased the risk in the preimplementation period. Nevertheless, the
measurement for both periods was performed using a standardized
protocol. Third, the implementation of the bundle was imperfect
and varied across the participating sites. Identiﬁcations of the
barriers to its implementation merit further investigations. Fourth,
as with any observational study, the causal inference might have
been confounded by time-varying factors (eg, an increase in
comorbidities over time). An RCT—with perfect adherence to the
assigned intervention, no selection bias due to a differential loss to
follow-up, and no postrandomization confounding—would yield
a consistent estimate for the causal effect of interest. Fifth, the
secular trend in asthma management may have affected the
observed improvement in the patient outcomes. However,
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the observed 30% reduction in the primary outcome is unlikely to
be fully explained by the secular change in asthma management
alone. Sixth, in this current study, the sample size was not large.
Regardless, we successfully identiﬁed signiﬁcant effects of the
bundle on the rate of severe asthma exacerbation. Lastly, our study
sample comprised patients with frequent severe exacerbations in
inner-city settings and excluded those with suboptimal medication
adherence. Therefore, our inference might not be generalized to
patients with mild-to-moderate asthma exacerbations or those
with suboptimal adherence in nonurban or nonacademic hospitals. Nonetheless, our target population has a substantial asthma
morbidity burden,44 and hence, is the one for which targeted
interventions are most urgently needed.

CONCLUSIONS
In sum, by applying a self-controlled case series method to
prospective multicenter data of adults hospitalized for asthma
exacerbation, we found that the implementation of an evidencebased asthma care bundle during hospitalization—an important
opportunity for preventive care—was associated with signiﬁcantly improved quality of asthma care and reduced rate of severe
asthma exacerbation over the 1-year postimplementation period.
These ﬁndings support a cautious optimism that the quality of
asthma care can be further improved and asthma morbidity
mitigated. For researchers, our study should advance research
into building more robust evidence on hospital-initiated asthma
care and identifying barriers for its implementation. For clinicians and hospitals, our data underscore the importance of
continued efforts on the development and implementation of
high-quality asthma care, which will, in turn, improve the outcomes of this population with large morbidity burden.
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TABLE E1. Implementation of a hospital-initiated care bundle by
item in patients hospitalized for asthma exacerbation
Bundle item

% (95% CI)

Core elements
Inpatient laboratory testing*
Serum total IgE measurement
CBC with differential measurement
Inpatient asthma education†
Development of written action plan
Education of inhaler use technique
Provision of peak ﬂowmeterz
Smoking cessation assistancex
Hospital discharge carek
Prescription of systemic corticosteroids
Modiﬁcation of ICS
Instruction for follow-up visit to asthma specialist
Appointment of follow-up visit to asthma specialist
Optional elements
Pharmacy consult
Asthma case manager consult

97
75
93
82
54
44
54
59
96
92
23
67
31
38
15
31

(92-99)
(65-83)
(87-97)
(73-89)
(44-64)
(34-54)
(33-73)
(36-79)
(90-99)
(85-97)
(16-33)
(57-76)
(22-41)
(29-48)
(8-23)
(22-41)

CBC, Complete blood count.
*Any of the following 2 items.
†Any of the following 4 items. Asthma education was performed by the multidisciplinary project team (eg, emergency physicians, internists, allergists/immunologists, pulmonologists, respiratory therapists, advanced practice providers, study staff)
during the index hospitalization.
zAmong 26 patients who did not have a peak ﬂowmeter at hospitalization.
xAmong 22 patients who were current smokers.
kAny of the following 4 items.
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TABLE E2. Within-individual comparisons of chronic asthma care between pre- and post-implementation periods, by sex
Rate (%)
Outcome by sex

Female (n ¼ 74)
Serum speciﬁc IgE measurement
Allergen skin testing
Use of omalizumab
Use of anti-IL-4/IL-5 therapyx
Asthma specialist visitk
Male (n ¼ 29)
Serum speciﬁc IgE measurement
Allergen skin testing
Use of omalizumab
Use of anti-IL-4/IL-5 therapyx
Asthma specialist visitk

Preimplementation*

Postimplementation†

RR (95% CI)z

P value

7
1
<1
<1
20

11
1
0
5.4
54

1.45 (0.56-3.59)
1.00 (0.05-10.5)
NA
8.00 (0.89-71.6)
2.76 (1.72-4.49)

.42
.99
NA
.06
<.001

2
0
3
0
19

17
0
3
3
45

10.2 (1.64-194.7)
NA
1.02 (0.05-10.6)
NA
2.41 (1.08-5.48)

.03
NA
.99
NA
.03

NA, Not estimated given the absence of an outcome in a period.
*Averaged over the 2-y period (a total of 206 person-years) before the implementation of the hospital-initiated care bundle.
†In the 1-y period (a total of 102.5 person-years) after the implementation of the hospital-initiated care bundle (including the index hospitalization).
zRRs are for post- vs pre- (reference) implementation periods within individuals, as estimated by conditional Poisson regression models accounting for the difference in period
intervals.
xIncluding dupilumab, benralizumab, mepolizumab, and reslizumab.
kIncluding allergists, pulmonologists, and asthma clinic providers.

TABLE E3. Within-individual comparisons of chronic asthma care between pre- and post-implementation periods, by race/ethnicity
Rate (%)
Outcome by race/ethnicity*

Non-Hispanic White (n ¼ 19)
Serum speciﬁc IgE measurement
Allergen skin testing
Use of omalizumab
Use of anti-IL-4/IL-5 therapyk
Asthma specialist visit{
Non-Hispanic Black (n ¼ 69)
Serum speciﬁc IgE measurement
Allergen skin testing
Use of omalizumab
Use of anti-IL-4/IL-5 therapyk
Asthma specialist visit{
Hispanic (n ¼ 12)
Serum speciﬁc IgE measurement
Allergen skin testing
Use of omalizumab
Use of anti-IL-4/IL-5 therapyk
Asthma specialist visit{

Preimplementation†

Postimplementationz

RR (95% CI)x

P value

5
3
3.0
0
32

16
0
0
16
58

3.07 (0.51-23.3)
NA
NA
NA
1.88 (0.82-4.30)

.22
NA
NA
NA
.13

7
<1
<1
<1
18

12
0
0
3
54

1.78 (0.67-4.65)
NA
NA
4.00 (0.38-86.0)
2.96 (1.79-4.97)

.24
NA
NA
.26
<.001

4
0
4
0
8

8
8
0
0
25

2.00 (0.08-50.5)
NA
NA
NA
3.00 (0.50-22.8)

.62
NA
NA
NA
.23

NA, Not estimated given the absence of an outcome in a period.
*There were only 3 patients in the other race/ethnicity category; therefore, no statistical inference was made.
†Averaged over the 2-y period (a total of 206 person-years) before the implementation of hospital-initiated care bundle.
zIn the 1-y period (a total of 102.5 person-years) after the implementation of the hospital-initiated care bundle (including the index hospitalization).
xRRs are for post- vs pre- (reference) implementation periods within individuals, as estimated by conditional Poisson regression models accounting for the difference in period
intervals.
kIncluding dupilumab, benralizumab, mepolizumab, and reslizumab.
{Including allergists, pulmonologists, and asthma clinic providers.
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TABLE E4. Within-individual comparisons of chronic asthma care between pre- and post-implementation periods, by primary health
insurance
Rate (%)
Outcome by insurance*

RR (95% CI)x

P value

Preimplementation†

Postimplementationz

7
<1
2
<1
19

11
2
2
3
47

1.76
2.02
1.01
4.03
2.44

(0.62-4.91)
(0.08-50.9)
(0.05-10.5)
(0.39-86.7)
(1.42-4.22)

.27
.62
.99
.26
.001

5
1
1
0
21

16
0
0
8
58

3.00 (0.86-11.7)
NA
NA
NA
2.75 (1.45-5.32)

.09
NA
NA
NA
.002

Public insurance (n ¼ 62)
Serum speciﬁc IgE measurement
Allergen skin testing
Use of omalizumab
Use of anti-IL-4/IL-5 therapyk
Asthma specialist visit{
Private insurance (n ¼ 38)
Serum speciﬁc IgE measurement
Allergen skin testing
Use of omalizumab
Use of anti-IL-4/IL-5 therapyk
Asthma specialist visit{

NA, Not estimated given the absence of an outcome in a period.
*There were only 3 patients with no insurance; therefore, no statistical inference was made.
†Averaged over the 2-y period (a total of 206 person-years) before the implementation of the hospital-initiated care bundle.
zIn the 1-y period (a total of 102.5 person-years) after the implementation of the hospital-initiated care bundle (including the index hospitalization).
xRRs are for post- vs pre- (reference) implementation periods within individuals, as estimated by conditional Poisson regression models accounting for the difference in period
intervals.
kIncluding dupilumab, benralizumab, mepolizumab, and reslizumab.
{Including allergists, pulmonologists, and asthma clinic providers.

TABLE E5. Within-individual comparisons of annualized incidence of severe asthma exacerbations between pre- and postimplementation
periods, by sex
Mean annualized incidence (per person-year)
Outcome by sex*

Female (n ¼ 74)
Systemic corticosteroid use
ED visit
Hospitalization
Male (n ¼ 29)
Systemic corticosteroid use
ED visit
Hospitalization

Preimplementation†

Postimplementationz

RR (95% CI)x

P value

4.0
3.4
2.2

2.8
2.5
1.6

0.71 (0.60-0.83)
0.73 (0.62-0.86)
0.76 (0.61-0.93)

<.001
<.001
.01

4.7
2.8
2.1

3.2
3.2
2.0

0.69 (0.54-0.87)
1.12 (0.87-1.45)
0.97 (0.71-1.33)

.002
.37
.87

*Test for the interactions between the care bundle and sex: Pinteraction ¼ .86 for systemic corticosteroid use, Pinteraction ¼ .01 for ED visit, and Pinteraction ¼ .20 for hospitalization.
†Averaged over the 2-y period (a total of 206 person-years) before the implementation of the hospital-initiated care bundle.
zIn the 1-y period (a total of 102.5 person-years) after the implementation of the hospital-initiated care bundle.
xRRs are for post- vs pre- (reference) implementation periods within individuals, as estimated by conditional Poisson regression models accounting for the difference in period
intervals.

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on August 30, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

NANISHI ET AL

J ALLERGY CLIN IMMUNOL PRACT
VOLUME -, NUMBER -

7.e4

TABLE E6. Within-individual comparisons of annualized incidence of severe asthma exacerbations between pre- and postimplementation
periods, by race/ethnicity
Mean annualized incidence (per person-year)
Outcome by race/ethnicity*

Non-Hispanic White (n ¼ 19)
Systemic corticosteroid use
ED visit
Hospitalization
Non-Hispanic Black (n ¼ 69)
Systemic corticosteroid use
ED visit
Hospitalization
Hispanic (n ¼ 12)
Systemic corticosteroid use
ED visit
Hospitalization

Preimplementation†

Postimplementationz

RR (95% CI)x

P value

3.8
4.0
2.8

3.1
2.1
1.5

0.85 (0.63-1.15)
0.51 (0.35-0.72)
0.54 (0.35-0.81)

.31
<.001
.004

4.2
3.1
2.2

3.1
3.1
2.1

0.74 (0.63-0.86)
0.99 (0.84-1.16)
0.96 (0.79-1.17)

<.001
.87
.69

5.3
3.0
1.3

1.8
1.2
0.4

0.35 (0.22-0.54)
0.38 (0.21-0.66)
0.32 (0.11-0.76)

<.001
.001
.02

*There were only 3 patients in the other race/ethnicity category; therefore, no statistical inference was made. Test for the interactions between the bundle and the race/ethnicity:
in non-Hispanic Black patients, Pinteraction ¼ .39 for systemic corticosteroid use, Pinteraction < .001 for ED visit, and Pinteraction ¼ .02 for hospitalization; in Hispanic patients,
Pinteraction ¼ .001 for systemic corticosteroid use, for Pinteraction ¼ .41 for ED visit, and Pinteraction ¼ .32 for hospitalization.
†Averaged over the 2-y period (a total of 206 person-years) before the implementation of the hospital-initiated care bundle.
zIn the 1-y period (a total of 102.5 person-years) after the implementation of the hospital-initiated care bundle.
xRRs are for post- vs pre- (reference) implementation periods within individuals, as estimated by conditional Poisson regression models accounting for the difference in period
intervals.

TABLE E7. Within-individual comparisons of annualized incidence of severe asthma exacerbations between pre- and postimplementation
periods, by primary health insurance
Mean annualized incidence (per person-year)
Outcome by insurance*

Public insurance (n ¼ 62)
Systemic corticosteroid use
ED visit
Hospitalization
Private insurance (n ¼ 38)
Systemic corticosteroid use
ED visit
Hospitalization

Preimplementation†

Postimplementationz

RR (95% CI)x

P value

4.7
3.8
2.8

3.0
3.1
2.4

0.64 (0.54-0.75)
0.81 (0.68-0.95)
0.85 (0.70-1.03)

<.001
.01
.10

3.4
2.3
1.1

2.8
2.0
0.8

0.81 (0.64-1.01)
0.88 (0.67-1.15)
0.73 (0.48-1.09)

.06
.35
.13

*There were only 3 patients with no insurance; therefore, no statistical inference was made. Test for the interactions between the care bundle and primary health insurance:
Pinteraction ¼ .04 for systemic corticosteroid use, Pinteraction ¼ .58 for ED visit, and Pinteraction ¼ .40 for hospitalization.
†Averaged over the 2-y period (a total of 206 person-years) before the implementation of the hospital-initiated care bundle.
zIn the 1-y period (a total of 102.5 person-years) after the implementation of the hospital-initiated care bundle.
xRRs are for post- vs pre- (reference) implementation periods within individuals, as estimated by conditional Poisson regression models accounting for the difference in period
intervals.
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TABLE E8. Within-individual comparisons of annualized incidence of severe asthma exacerbations between pre- and postimplementation
periods, by smoking status
Mean annualized incidence (per person-year)
Outcome by smoking status*

Nonsmoking (n ¼ 75)
Systemic corticosteroid use
ED visit
Hospitalization
Smoking (n ¼ 22)
Systemic corticosteroid use
ED visit
Hospitalization

Preimplementation†

Postimplementationz

RR (95% CI)x

P value

4.4
3.4
2.2

3.3
3.0
2.0

0.75 (0.65-0.86)
0.89 (0.76-1.03)
0.93 (0.76-1.12)

<.001
.13
.45

3.3
2.4
1.9

1.7
1.9
1.2

0.52 (0.36-0.74)
0.78 (0.54-1.11)
0.62 (0.39-0.95)

<.001
.18
.03

*Among 97 patients who had the information of smoking status. Test for the interactions between the care bundle and the smoking status: Pinteraction ¼ .08 for systemic
corticosteroid use, Pinteraction ¼ .53 for ED visit, and Pinteraction ¼ .10 for hospitalization.
†Averaged over the 2-y period (a total of 150 person-years in the nonsmoking group and a total of 44 person-years in the smoking group) before the implementation of the
hospital-initiated care bundle.
zIn the 1-y period (a total of 75 person-years in the nonsmoking group and a total of 21.5 person-years in the smoking group) after the implementation of the hospital-initiated
care bundle.
xRRs are for post- vs pre- (reference) implementation periods within individuals, as estimated by conditional Poisson regression models accounting for the difference in period
intervals.

TABLE E9. Within-individual comparisons of annualized incidence of severe asthma exacerbations between pre- and postimplementation
periods, by obesity status
Mean annualized incidence (per person-year)
Outcome by obesity status*

Nonobesity (n ¼ 28)
Systemic corticosteroid use
ED visit
Hospitalization
Obesity (n ¼ 62)
Systemic corticosteroid use
ED visit
Hospitalization

Preimplementation†

Postimplementationz

RR (95% CI)x

P value

4.8
2.5
1.9

3.6
3.5
2.0

0.75 (0.59-0.94)
1.38 (1.06-1.78)
1.04 (0.75-1.43)

.02
.02
.83

4.2
3.8
2.5

2.8
2.7
2.0

0.68 (0.57-0.80)
0.72 (0.60-0.85)
0.77 (0.62-0.94)

<.001
<.001
.01

BMI, Body mass index.
*Among 90 patients who had the information of body height and weight. Obesity was deﬁned by BMI of  30 kg/m2. Test for the interactions between the care bundle and the
obesity status: Pinteraction ¼ .49 for systemic corticosteroid use, Pinteraction < .001 for ED visit, and Pinteraction ¼ .12 for hospitalization.
†Averaged over the 2-y period (a total of 56 person-years in the nonobesity group and a total of 124 person-years in the obesity group) before the implementation of the hospitalinitiated care bundle.
zIn the 1-y period (a total of 28 person-years in the nonobesity group and a total of 61.5 person-years in the obesity group) after the implementation of the hospital-initiated care
bundle.
xRRs are for post- vs pre- (reference) implementation periods within individuals, as estimated by conditional Poisson regression models accounting for the difference in period
intervals.
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TABLE E10. Within-individual comparisons of annualized incidence of severe asthma exacerbations between pre- and
postimplementation periods, by history of intubation for asthma
Mean annualized incidence (per person-year)
Outcome by history of intubation for asthma*

Preimplementation†

Postimplementationz

RR (95% CI)x

P value

4.0
2.6
1.5

2.7
2.2
1.3

0.68 (0.57-0.79)
0.88 (0.73-1.05)
0.83 (0.65-1.06)

<.001
.16
.14

4.7
4.9
3.6

3.5
3.8
3.0

0.76 (0.60-0.94)
0.77 (0.62-0.96)
0.81 (0.63-1.04)

.01
.02
.10

No history of intubation (n ¼ 72)
Systemic corticosteroid use
ED visit
Hospitalization
History of intubation (n ¼ 30)
Systemic corticosteroid use
ED visit
Hospitalization

*Among 102 patients who have the information of history of intubation for asthma. Test for the interactions between the care bundle and the history of intubation for asthma:
Pinteraction ¼ .42 for systemic corticosteroid use, Pinteraction ¼ .39 for ED visit, and Pinteraction ¼ .90 for hospitalization.
†Averaged over the 2-y period (a total of 144 person-years in the no-history of intubation group and a total of person-years in the history of intubation group) before the
implementation of the hospital-initiated care bundle.
zIn the 1-y period (a total of 71.5 person-years in the no history of intubation group and a total of 30 person-years in the history of intubation group) after the implementation of
the hospital-initiated care bundle.
xRRs are for post- vs pre- (reference) implementation periods within individuals, as estimated by conditional Poisson regression models accounting for the difference in period
intervals.

TABLE E11. Within-individual comparisons of annualized incidence of severe asthma exacerbations between pre- and
postimplementation periods, by use of oral corticosteroids before index hospitalization
Mean annualized incidence (per person-year)
Outcome by use of oral corticosteroids*

No use of oral corticosteroids (n ¼57)
Systemic corticosteroid use
ED visit
Hospitalization
Use of oral corticosteroids (n ¼ 45)
Systemic corticosteroid use
ED visit
Hospitalization

Preimplementation†

Postimplementationz

RR (95% CI)x

P value

4.7
3.6
2.4

3.1
2.9
2.0

0.67 (0.56-0.79)
0.79 (0.65-0.94)
0.85 (0.68-1.06)

<.001
.009
.15

3.6
2.8
1.9

2.7
2.5
1.4

0.76 (0.62-0.93)
0.90 (0.72-1.12)
0.76 (0.57-1.01)

.01
.34
.07

*Among 102 patients who have the information of use of oral corticosteroids before the index hospitalization. Test for the interactions between the care bundle and the use of
oral corticosteroids: Pinteraction ¼ .35 for systemic corticosteroid use, Pinteraction ¼ .37 for ED visit, and Pinteraction ¼ .56 for hospitalization.
†Averaged over the 2-y period (a total of 114 person-years in the nonuse of oral corticosteroids group and a total of 90 person-years in the use of oral corticosteroids group)
before the implementation of the hospital-initiated care bundle.
zIn the 1-y period (a total of 56.5 person-years in the nonuse of oral corticosteroids group and a total of 45 person-years in the use of oral corticosteroids group) after the
implementation of the hospital-initiated care bundle.
xRRs are for post- vs pre- (reference) implementation periods within individuals, as estimated by conditional Poisson regression models accounting for the difference in period
intervals.
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TABLE E12. Within-individual comparisons of annualized incidence of severe asthma exacerbations between pre- and
postimplementation periods, by initial hospitalization location
Mean annualized incidence (per person-year)
Outcome by initial hospitalization location*

Preimplementation†

Postimplementationz

RR (95% CI)x

P value

4.4
2.6
1.4

3.0
2.4
1.3

0.69 (0.57-0.82)
0.92 (0.75-1.13)
0.90 (0.68-1.18)

<.001
.43
.45

4.1
3.6
3.0

3.0
3.3
2.4

0.73 (0.58-0.91)
0.93 (0.75-1.16)
0.80 (0.62-1.02)

.01
.52
.08

3.4
4.9
2.7

2.3
1.8
1.8

0.69 (0.44-1.05)
0.37 (0.23-0.58)
0.68 (0.41-1.08)

.09
<.001
.11

ED observation unit (n ¼ 55)
Systemic corticosteroid use
ED visit
Hospitalization
Hospital ward or stepdown unit (n ¼ 36)
Systemic corticosteroid use
ED visit
Hospitalization
Intensive care unit (n ¼ 12)
Systemic corticosteroid use
ED visit
Hospitalization

*Test for the interactions between the bundle and the initial hospitalization location: in hospital ward or stepdown, Pinteraction ¼ .66 for systemic corticosteroid use, Pinteraction ¼
.94 for ED visit, and Pinteraction ¼ .55 for hospitalization; in intensive care unit, Pinteraction ¼ .97 for systemic corticosteroid use, for Pinteraction < .001 for ED visit, and
Pinteraction ¼ .32 for hospitalization.
†Averaged over the 2-y period (a total of 110 person-years in the ED observation unit group, a total of 72 person-years in the hospital ward or stepdown unit group, and a total of
24 person-years in the intensive care unit group) before the implementation of the hospital-initiated care bundle.
zIn the 1-y period (a total of 55 person-years in the ED observation unit group, a total of 35.5 person-years in the hospital ward or stepdown unit group, and a total of 12 personyears in the intensive care unit group) after the implementation of the hospital-initiated care bundle.
xRRs are for post- vs pre- (reference) implementation periods within individuals, as estimated by conditional Poisson regression models accounting for the difference in period
intervals.

TABLE E13. Within-individual comparisons of the annualized incidence of severe asthma exacerbations between pre- and
postimplementation periods in patients without COPD
Mean annualized incidence (per person-year)
Outcomes

Systemic corticosteroid use
ED visit
Hospitalization

Preimplementation*

Postimplementation†

RR (95% CI)z

P value

3.9
3.3
2.0

2.6
2.4
1.5

0.68 (0.58-0.78)
0.74 (0.63-0.86)
0.75 (0.62-0.92)

<.001
<.001
.01

*Averaged over the 2-y period (a total of 180 person-years) before the implementation of the hospital-initiated care bundle.
†In the 1-y period (a total of 90.5 person-years) after the implementation of the hospital-initiated care bundle.
zRRs are for post- vs pre- (reference) implementation periods within individuals, as estimated by conditional Poisson regression models accounting for the difference in period
intervals.

TABLE E14. Within-individual comparisons of annualized incidence of severe asthma exacerbations between pre- and
postimplementation periods in patients who did not initiate new biologic agents in the postimplementation period*
Mean annualized incidence (per person-year)
Outcome

Systemic corticosteroid use
ED visit
Hospitalization

Preimplementation†

Postimplementationz

RR (95% CI)x

P value

4.2
3.1
2.0

2.9
2.7
1.8

0.71 (0.62-0.81)
0.76 (0.72-1.02)
0.88 (0.73-1.05)

<.001
.10
.15

*Deﬁned as anti-IL-4/IL-5 therapy including dupilumab, benralizumab, mepolizumab, and reslizumab.
†Averaged over the 2-y period (a total of 196 person-years) before the implementation of the hospital-initiated care bundle.
zIn the 1-y period (a total of 97.5 person-years) after the implementation of the hospital-initiated care bundle.
xRRs are for post- vs pre- (reference) implementation periods within individuals, as estimated by conditional Poisson regression models accounting for the difference in period
intervals.
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TABLE E15. Within-individual comparisons of the annualized incidence of severe asthma exacerbations between pre- and
postimplementation (0-6 mo after index hospitalization) periods
Mean annualized incidence (per person-year)
Outcome

Systemic corticosteroid use
ED visit
Hospitalization

Preimplementation*

Postimplementation†

RR (95% CI)z

P value

4.2
3.2
2.1

3.1
2.8
2.0

0.74 (0.63-0.88)
0.88 (0.73-1.05)
0.93 (0.75-1.15)

<.001
.15
.52

*Averaged over the 2-y period (a total of 206 person-years) before the implementation of the hospital-initiated care bundle.
†In the ﬁrst 6-mo period after the implementation of the hospital-initiated care bundle (a total of 51.5 person-years).
zRRs are for post- vs pre- (reference) implementation periods within individuals, as estimated by conditional Poisson regression models accounting for the difference in period
intervals.

TABLE E16. Within-individual comparisons of the annualized incidence of severe asthma exacerbations between pre- and
postimplementation (7-12 mo after index hospitalization) periods
Mean annualized incidence (per person-year)
Outcome

Systemic corticosteroid use
ED visit
Hospitalization

Preimplementation*

Postimplementation†

RR (95% CI)z

P value

4.2
3.2
2.1

2.7
2.5
1.5

0.66 (0.55-0.79)
0.77 (0.64-0.93)
0.70 (0.55-0.89)

<.001
.007
.004

*Averaged over the 2-y period (a total of 206 person-years) before the implementation of the hospital-initiated care bundle.
†In the second 6-mo period after the implementation of the hospital-initiated care bundle (a total of 51 person-years).
zRRs are for post- vs pre- (reference) implementation periods within individuals, as estimated by conditional Poisson regression models accounting for the difference in period
intervals.

TABLE E17. Within-individual comparisons of the proportion of severe asthma exacerbations occurrence between pre- and
postimplementation periods, modeling outcomes as binary variables
Proportion (%)
Outcome

Systemic corticosteroid use
ED visit
Hospitalization

Preimplementation

Postimplementation

OR (95% CI)*

P value

100
93
77

73
69
58

NA†
0.21 (0.07-0.70)
0.59 (0.27-1.30)

NA†
.01
.19

NA, Not applicable; OR, odds ratio.
*ORs for the occurrence of outcome event (yes vs no) for post- vs pre- (reference) implementation periods within individuals, as estimated by conditional logistic regression
models accounting for the difference in period intervals.
†Not estimated because all patients had a systemic corticosteroid use in the preimplementation period as an inclusion criterion.
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